0001209191-23-038141.txt : 20230616 0001209191-23-038141.hdr.sgml : 20230616 20230616200336 ACCESSION NUMBER: 0001209191-23-038141 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230615 FILED AS OF DATE: 20230616 DATE AS OF CHANGE: 20230616 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KANEKO YASUNORI CENTRAL INDEX KEY: 0001277503 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38419 FILM NUMBER: 231022981 MAIL ADDRESS: STREET 1: 509 ROEHAMPTON CITY: HILLS BOROUGH STATE: CA ZIP: 94010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Arcus Biosciences, Inc. CENTRAL INDEX KEY: 0001724521 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473898435 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3928 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: (510) 694-6200 MAIL ADDRESS: STREET 1: 3928 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-15 0 0001724521 Arcus Biosciences, Inc. RCUS 0001277503 KANEKO YASUNORI C/O ARCUS BIOSCIENCES, INC. 3928 POINT EDEN WAY HAYWARD CA 94545 1 0 0 0 0 Common Stock 2023-06-15 4 A 0 6800 0.00 A 6800 D Common Stock 505050 I By Kaneko Capital, LLC Common Stock 252524 I By Kaneko Investments, LLC Common Stock 146181 I By Trust Stock Option (Right to Buy) 19.60 2023-06-15 4 A 0 19500 0.00 A 2033-06-14 Common Stock 19500 19500 D Represents the grant of restricted stock units that vest in full on the earlier of June 15, 2024 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Includes 4,100 shares of restricted stock units (previously reported) that vested on June 14, 2023 and were subsequently transferred to the reporting person's trust. The option will vest in full on the earlier of June 15, 2024 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. /s/ Carolyn Tang, Attorney-in-Fact 2023-06-16